🚨 New Evidence Alert 🚨

The SWEDEPAD 1 & 2 trials + a powerful Lancet commentary have reshaped how we view paclitaxel-coated devices in peripheral artery disease.

👉 No benefit for amputation or quality of life.

👉 A concerning signal for higher 5-year mortality in claudication.

👉 Registry-based RCTs prove invaluable for real-world insights.

⚖️ Message: Harm may outweigh benefit — time to rethink strategies and explore alternatives like sirolimus.

#PAD #ClinicalTrials #Cardiology #SWEDEPAD 🫀